Research programme: chimeric antigen receptor T-cell therapies - bluebird bio/ViroMed

Drug Profile

Research programme: chimeric antigen receptor T-cell therapies - bluebird bio/ViroMed

Alternative Names: CAR T-cell therapies - bluebird bio/ViroMed

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator ViroMed Co Ltd
  • Developer bluebird bio
  • Class CAR-T cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Dec 2015 bluebirdbio in-licenses Chimeric antigen receptor T-cell therapies from ViroMed
  • 03 Dec 2015 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top